StockNews.com Begins Coverage on NovaBay Pharmaceuticals (NYSE:NBY)

Research analysts at StockNews.com assumed coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a note issued to investors on Friday. The brokerage set a “hold” rating on the stock.

Separately, Ascendiant Capital Markets lowered their price objective on shares of NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating for the company in a research report on Monday, November 11th.

NovaBay Pharmaceuticals Stock Up 1.7 %

Shares of NBY stock opened at $0.58 on Friday. The firm has a fifty day moving average of $0.63 and a 200-day moving average of $0.96. NovaBay Pharmaceuticals has a 12-month low of $0.36 and a 12-month high of $9.08. The company has a market capitalization of $2.83 million, a price-to-earnings ratio of -0.01 and a beta of 0.69.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.